Immediate Impact
6 from Science/Nature 55 standout
Citing Papers
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
2024 Standout
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
2024 Standout
Works of Kees Bol being referenced
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.
2020
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Kees Bol | 272 | 129 | 254 | 221 | 10 | 526 | |
| Karin E. Summers | 277 | 68 | 138 | 162 | 11 | 600 | |
| Robert H. Gersh | 150 | 28 | 187 | 202 | 8 | 495 | |
| Richard Smykla | 279 | 33 | 201 | 223 | 16 | 633 | |
| Koorosh Korfi | 142 | 38 | 219 | 237 | 17 | 526 | |
| Marise Weil | 188 | 56 | 247 | 229 | 10 | 574 | |
| Angela Douglas | 114 | 55 | 130 | 112 | 10 | 464 | |
| Bühring Hj | 136 | 37 | 207 | 275 | 12 | 530 | |
| Nadine Juge‐Morineau | 264 | 41 | 160 | 227 | 18 | 547 | |
| Alice B. Salter | 108 | 115 | 260 | 276 | 9 | 596 | |
| M L Banquerigo | 110 | 89 | 237 | 230 | 10 | 614 |
All Works
Loading papers...